Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Amit Bhojwani

Otolaryngology Bryn Mawr, PA Doctor of Osteopathy

NPI 1477986420 CMS profile 4219661

830 Old Lancaster Rd, Suite 200 North Bldg, Bryn Mawr, PA 19010

Open in the dashboard

General payments

$31,010

98 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Amit Bhojwani of Bryn Mawr, PA is reported in the CMS Open Payments database as having received $31,010 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $6,537 14
2023 General $2,030 18
2022 General $575 35
2021 General $563 26
2020 General $45 2
2019 General $21,261 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amit Bhojwani
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Amit Bhojwani were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Amit Bhojwani Otolaryngology median Middle half National median
2019 $21,261 $194 $82–$512 $163
2020 $45 $118 $42–$280 $114
2021 $563 $167 $63–$444 $132
2022 $575 $216 $84–$545 $149
2023 $2,030 $235 $93–$588 $160
2024 $6,537 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. KLS-Martin L.P. $21,250 2 payments
  2. Intuitive Surgical, Inc. $8,442 26 payments
  3. OptiNose US, Inc. $694 40 payments
  4. Regeneron Healthcare Solutions, Inc. $311 14 payments
  5. Genzyme Corporation $124 6 payments
  6. ALK-Abello, Inc $41 2 payments
  7. GlaxoSmithKline, LLC. $38 2 payments
  8. Smith+Nephew, Inc. $34 1 payment
  9. Nalu Medical, Inc. $25 1 payment
  10. Cook Medical LLC $22 2 payments
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Grant $21,250 2 payments
  2. Education $5,500 3 payments
  3. Travel and Lodging $2,677 16 payments
  4. Food and Beverage $1,583 77 payments
Products named General payments · program years 2019–2024
  1. DA VINCI SP $5,500 3 payments
  2. Da Vinci Surgical System $2,942 23 payments
  3. Xhance $694 40 payments
  4. DUPIXENT Inflammation And Immunology $311 14 payments
  5. DUPIXENT Immunology $207 10 payments
  6. Odactra $41 2 payments
  7. Grastek $41 2 payments
  8. Otiprio $41 2 payments
  9. NUCALA $38 2 payments
  10. PROCISE Tonsil $34 1 payment
  11. Other $48 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

671

Median for Otolaryngology: 297

Drug cost

$18,606

Median for Otolaryngology: $6,314

Branded share of claims

2.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 258 $10,023
Ipratropium Bromide Generic 91 $3,117
Mometasone Furoate Generic 26 $1,625
Fluocinolone Acetonide Generic 21 $920
Baclofen Generic 93 $627
Famotidine Generic 48 $622
Omeprazole Generic 52 $549
Triamcinolone Acetonide Generic 14 $301
Fluticasone Propionate Generic 11 $265
Pantoprazole Sodium Generic 14 $258

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$129,302

Medicare's payments for the services billed

Medicare patients

492

Average age 76

Services billed

1,198

295 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 52%
Ischemic heart disease 36%
Osteoporosis 24%
Chronic kidney disease 22%
Diabetes 20%
Depression 20%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record